Professional Documents
Culture Documents
63]
Review Article
Department of ABSTRACT
Dermatology and
Venereology, AIIMS, The prevalence of superficial mycotic infection worldwide is 2025% of which dermatophytes are the most
NewDelhi, 1Department common agents. Recent developments in understanding the pathophysiology of dermatophytosis have confirmed
of Dermatology, the central role of cellmediated immunity in countering these infections. Hence, a lack of delayed hypersensitivity
Venereology, and reaction in presence of a positive immediate hypersensitivity(IH) response to trichophytin antigen points
Leprology, Postgraduate
toward the chronicity of disease. Diagnosis, though essentially clinical should be confirmed by laboratorybased
Institute of Medical
investigations. Several new techniques such as polymerase chain reaction(PCR) and mass spectroscopy can
Education and Research,
Chandigarh, India help to identify the different dermatophyte strains. Management involves the use of topical antifungals in limited
disease, and oral therapy is usually reserved for more extensive cases. The last few years have seen a significant
rise in the incidence of chronic dermatophyte infections of skin which have proven difficult to treat. However,
due to the lack of updated national or international guidelines on the management of tinea corporis, cruris, and
pedis, treatment with systemic antifungals is often empirical. The present review aims to revisit this important
topic and will detail the recent advances in the pathophysiology and management of tinea corporis, tinea cruris,
and tinea pedia while highlighting the lack of clarity of certain management issues.
Key words: Dermatophytosis, superficial fungal infections, tinea corporis, tinea cruris, tinea pedis
present review aims to revisit this important topic and will detail serinesubtilisins, and fungolysin, which causes digestion of
the recent advances in the pathophysiology and management keratin network into oligopeptide or aminoacid and also act
of tinea corporis, tinea cruris, and tinea pedis while highlighting as a potent immunogenic stimuli.[15] In addition, the mannans
the lack of clarity of certain management issues. produced by T. rubrum lead to inhibition of lymphocytes.
Impaired function of Th17cells leading decreased production
CHANGING EPIDEMIOLOGY OF of interleukin17 (IL17), IL22 (key cytokine in clearing
DERMATOPHYTOSIS mucocutaneous fungal infection) results in persistence of
infection.[15]
Dermatophytes are the most common agents of superficial
fungal infections worldwide and widespread in the developing Immunology of dermatophytosis
countries, especially in the tropical and subtropical countries The immune response to infection by dermatophytes ranges
like India, where the environmental temperature and relative from a nonspecific host mechanism to a humoral and
humidity are high. Other factors such as increased urbanization cellmediated immune response. The currently accepted view
including the use of occlusive footwear and tight fashioned is that a cellmediated immune response is responsible for the
clothes, has been linked to higher prevalence.[9] Over the control of dermatophytosis.
last few years, studies on epidemiology of dermatophytic
infection from different part of India have shown a rising trend Innate immune response
in the prevalence of cutaneous dermatophytosis with change Dermatophytes contain cell wall carbohydrate
in spectrum of infection and isolation of some uncommon molecules(glucan) that are recognized by innate immune
species.[1013] Trichophyton rubrum continues to be the most mechanisms, such as Dectin1 and Dectin2, which activate
common isolate with tinea corporis and cruris the most tolllike receptor 2 and 4 (TLR2 and TLR4). Dectin1
common clinical presentation in relatively large studies from amplifies the production of tumor necrosis factor and
Chennai and Rajasthan. However, in studies from Lucknow and IL17, IL6, and IL10, all of which stimulate the adaptive
NewDelhi, Trichophytonmentagrophytes[13] and Microsporum immunity.[16,17] Keratinocytes in the presence of dermatophyte
audouinii[11] were the most frequent isolate. Few studies also antigens, such as trichophytin, release IL8, a potent
showed isolation of rare species like Microsporum gypseum neutrophillic chemoattractant. Arecent study shows the
in nonendemic part of the world.[11] involvement of TLR2 and TLR4 in localized and disseminated
dermatophytosis due to T. rubrum. Areduced expression of
PATHOGENESIS OF DERMATOPHYTOSIS TLR4 in the lower and upper epidermis of both localized and
disseminated dermatophytosis patients was found compared
Genetics of dermatophytosis to controls; TLR2 expression was preserved in the upper and
All people are not equally susceptible to fungal infection, lower epidermis of all three groups.[18,19]
even when they have similar risk factors. There is evidence of
familial or genetic predispositions that could be mediated by Adaptive immune response
specific defects in innate and adaptive immunity. One of the Humoral immunity: Humoral immunity to dermatophytes
first fungal diseases thought to have a genetic predisposition is not protective. High levels of specific IgE and IgG4 are
was Tokelau or tinea imbricata. According to Jaradatetal., detected in patients with chronic dermatophytosis which
patients with low defensin beta 4 may be predisposed to all is responsible for positive (IgE mediated) IH tests to
dermatophytes.[14] Trichophyton. On the other hand, Ig levels are low in patients
that present positive delayed type hypersensitivity(DTH)
The pathogenesis of dermatophyte infection involves complex skin test. The IH skin test for Trichophyton is associated with
interaction between the host, agent and the environment. the presence of serum IgE and IgG(mostly IgG4) against
The factors which predispose to such an infection are Trichophyton antigens, hallmarks of a Th2 response. Here,
underlying diseases such as diabetes mellitus, lymphomas, IL4 produced by CD4 Tcells(Th2cells) induces antibody
immunocompromised status, or Cushings syndrome, older isotype switching to IgG4 and IgE
age, which could produce severe, widespread, or recalcitrant Cellmediated immunity: Several experiments have shown
dermatophytosis. Some areas of the body are more that the resolution of dermatophytosis is mediated by DTH.
susceptible to the development of dermatophyte infections Immunity to pathogens could be regulated by Th1 or Th2
such as intertriginous areas(web spaces and groins) where subsets which would ultimately determine the outcome of
excess sweating, maceration, and alkaline pH favor the the infection. An acute inflammatory response correlates
growth of the fungus. After inoculation into the host skin, with a positive DTH skin test to trichophytin and clearing of
suitable condition favor the infection to progress through the infection whereas chronic infection is associated with
adherence followed by penetration mediated by proteases, high IH and low DTH.[17]
infection but also help in determining drug resistance,[25] and TREATMENT OF CUTANEOUS
include:
DERMATOPHYTOSIS
Uniplex PCR for direct dermatophyte detection in clinical
samples: APCR for the direct detection of dermatophytes
Nonpharmacologic measures
in skin scales is available as inhouse PCRELISA assay
Patients should be encouraged to wear loosefitting garments
which separately identifies numerous dermatophyte
made of cotton or synthetic materials designed to wick moisture
species. In a pilot study, the sensitivity and specificity of
away from the surface. Socks should have similar properties.
the test compared to cultures was 80.1% and 80.6%
Areas likely to become infected should be dried completely
Multiplex PCR for fungal detection in dermatophytes:
before being covered with clothes. Patients should also be
Commercially available multiplex PCR tests enable
advised to avoid walking barefoot and sharing garments.
simultaneous amplification of 21 dermatomycotic pathogens
with subsequent DNA detection by means of agarose gel
electrophoresis. Medical management with antifungals
A variety of traditional agents without specific antimicrobial
New molecular methods like matrixassisted laser function are still in use, including Whitfields ointment and
Castellanis (Carbol fuchsin solution) paint. The efficacy of
desorption ionizationtime of flight mass spectrometry
these preparations has not been well quantified.[28] Table1
It is based on the detection of biochemical characteristics,
summarizes the classification of commonly employed
proteolytic degradation product which is a result of the activity
antifungals.[2931] Lesions covering a large body surface area
of mycological infections or noninfectious diseases. These
are represented by proteolytic degradation products of native fail to clear with repeated treatment using different topical
proteins. The peptide patterns of affected samples are identified agents should be considered for systemic therapy.[28] There is
by comparison with known peptide spectra from skin disorders no definite comparative study on combination of systemic and
stored in an already existing database. This procedure is topical versus monotherapy with systemic antifungal treatment.
immensely time saving, as it enables simultaneous identification
of up to 64 dermatophyte strains, with results coming back Table1: Classification of antifungal therapy based
within 24h.[26] on their structure
Antifungal class Examples
Reflectance confocal microscopy Antibiotics
It provides invivo imaging of the epidermis and superficial Polyenes Amphotericin B, nystatin, natamycin
dermis at cellular level resolution and can be used to detect Heterocyclic Griseofulvin
cutaneous fungi and parasitic infestations.[27] Branching fungal benzofuran
hyphae can be detected over an erythematous annular scaly Antimetabolite Flucytosine
patch. Advantage of the test being noninvasive and in a Azoles
retrospective analysis of the test by Friedman etal. sensitivity Imidazoles Topicalclotrimazole, econazole, miconazole,
was found to be 100%. bifonazole, fenticonazole, oxiconazole,
tioconazole, sertaconazole, berconazole,
luliconazole, eberconazole
Summarizing it can be safely recommended that a clinical Systemicketoconazole
diagnosis of cutaneous dermatophytic infection should
Triazoles Itraconazole, fluconazole(also topical),
always be supplemented by a mycologic confirmation. While voriconazole, posaconazole, isavuconazole,
traditional methods like direct demonstration of fungus by KOH posoconazole, ravuconazole, pramiconazole,
albaconazol
offer a reasonably sensitive and inexpensive option, newer
noninvasive methods such as dermoscopy have additional Allylamines Terbinafine, butenafine, naftifine
advantage of ease of use, ability to detect involvement of Echinocandins Caspofungin, anidulafungin, micafungin,
aminocandin
vellus hair and thus, influence the choice of treatment(topical
Sordarin derivatives GR135402, GM237354
versus systemic). Fungal culture and antifungal testing
Cell wall antagonist Capsofungin, micafungin
are costlier and more specialized investigations, but such
Other agents Tolnaftate, ciclopirox, amorolfine, undecylenic
infrastructure needs to build up at most centers, especially
acid, buclosamide, Whitfields ointment, benzoyl
in the present scenario of rising prevalence of nonresponsive peroxide, zinc pyrithione, selenium sulfide,
dermatophytosis. Other methods such as PCR and reflectance azelaic acid etc., nikkomycins, icofungipen
confocal microscopy are still used primarily for research Newer and Demcidin, macrocarpal C
purposes. potential therapies
Topical medications have better pharmacokinetics than their are also effective in terms of clinical and mycological cure
systemic counterparts. Hence, combination is expected to have rates. Regarding combinations therapy of topical steroids and
better mycological clearance than systemic and topical alone. antifungals though there is no standard guideline.[3335] There
Combination should be from different groups for wide coverage is insufficient evidence to confidently assess relapse rates in
and also to prevent emergence of resistance. Drugs given for the individual or combination treatments. Difference between
shorter duration with higher dose there has a less chance of the different antifungals is mostly regarding fewer application
development of resistance compared to lower dose for longer and shorter duration of treatment with some class of topical
duration. Drug with keratophilic and lipophilic property, when antifungals compared to others. Topical antifungal are usually
given in higher doses will have reservoir effect and will lead to given once or twice daily for 24weeks as illustrated in Table2.
better mycological clearance. The end point of treatment is clinical resolution in most of the
cases.
Indication of systemic antifungals in dermatophytosis
Tinea capitis Moriarty etal., also emphasize upon the use of topical therapy
Tinea affecting the nails in treating tinea corporis, cruris and pedis. They also enlist the
Tinea involving more than one body region simultaneously, common reasons of failure of therapy, namely; poor adherence
for example, tinea cruris and corporis, or tinea cruris and to treatment, reinfection from close contact, drug resistance,
tinea pedis misdiagnosis, and infection with uncommon species. Such
Tinea corporis where the lesions are particularly extensive. patients should be referred to a higher center for appropriate
However, there is no accepted definition of extensive management. They also suggest use of topical hydrocortisone
disease for a short time in inflamed lesions. Studies have also shown
Tinea pedis when there is extensive involvement of the that addition of topical steroid also increases the bioavailability
sole, heel, or dorsum of the foot or when there is recurring of topical antifungals mostly imidazole groups in addition to
and troublesome blistering. better symptomatic relief in early inflammatory stage.[33] While
it may be of benefit to patients with inflammatory lesions, such
Topical antifungal therapy for tinea cruris, corporis, practice should be strongly discouraged in countries like India
and pedis where easy over the counter availability of topical steroids
Reviewing the evidence on the use of existing topical render then to frequent misuse by patients who finally end up
with tinea incognito. Steroids may helpful in initial improvement
antifungals
in symptoms but chronic use lead to a complication like
Various topical antifungal agents are available for the treatment
atrophy, telangiectasia which is more prominent when lesions
of localized tinea corporis, tineacruris, tinea faciei, and tinea
pedis. It may also be used as an adjunct to oral antifungals for are present in flexures. Topical antifungals with potent
more extensive infection. Most of the studies in the treatment of antiinflammatory action such as sertaconazole or luliconazole
tinea corporis and cruris have looked at the efficacy of topical may be a better option than an antifungalsteroid combination.
antifungals with very few studies on the use of oral antifungals.
Ametaanalysis by Rotta et al.[32] evaluated the efficacy of Tinea pedis is usually treated with a topical antifungal cream
antifungal treatment involving 14 different topical antifungals for 4weeks; interdigital tinea pedis may only require 1week of
and included 65 randomized controlled trials(RCTs), comparing therapy. Various topical antifungal effective against tinea pedis
topical antifungal with one another or with placebo. Efficacy include azoles, allylamines, butenafine, ciclopirox, tolnaftate,
was evaluated in the form of mycological cure at the end and amorolfine as evidenced by a metaanalysis finding
of treatment and sustained cure. They found no statistically strong evidence of superiority of topical antifungal agents over
significant differences among the antifungals concerning placebo.[7] A metaanalysis of 11 randomized trials concluded
the outcome of mycologic cure at the end of treatment. For that treatment with terbinafine or naftifine produces a slightly
sustained cure, butenafine and terbinafine each was found higher cure rate than treatment with an azole.[36] Nystatin is
to be superior to clotrimazole. Pairwise comparison of topical not effective for the treatment of dermatophyte infections.
antifungals for the outcome of fungal cure showed butenafine Naftifine hydrochloride gel was also found to be effective both
and terbinafine each to be superior to clotrimazole, oxiconazole, for interdigital and moccasin type of tinea pedis.[37]
and sertaconazole; terbinafine to be superior to ciclopirox, and
naftifine to be superior to oxiconazole. Newer topical antifungals
Luliconazole, an azole antifungal has fungicidal action against
Similarly, Cochrane review on the topical antifungal treatments
[6] Trichophyton species similar to or more than that of terbinafine.
for tinea cruris and tinea corporis suggests that the individual Available in 1% cream formulation, it is effective as once daily
treatments with terbinafine and naftifine are effective with few application for 12weeks for dematophytic infection. Approved
adverse effects. Other topical antifungals like azoles treatments by the US Food and Drug Administration for the treatment of
Table2: Summary of the use of topical antifungals used in the treatment of tinea corporis, cruris and pedis
Azole Preparations Site Frequency of application Duration of use
Imidazoles(%)
Clotrimazole(1) Cream, lotion T. corporis/cruris/pedis BD 4-6weeks
Econazole(1) Cream T. corporis/cruris/pedis ODBD 4-6weeks
Miconazole(1) Cream, lotion T. corporis/cruris/pedis BD 4-6weeks
Oxiconazole(2) Cream, lotion T. corporis/cruris/pedis ODBD 4weeks
Sertaconazole(2) Cream T. corporis/cruris/pedis BD 4weeks
Luliconazole(1) Cream, lotion T. corporis/cruris/pedis OD 2weeks
Eberconazole(1) Cream T. corporis/cruris/pedis OD 2-4weeks
Triazoles(%)
Efinaconazole(10) Solution T. pedis OD Up to 52weeks in
coexisting tinea unguium
Allylamines
Terbinafine Cream, powder T. corporis BD 2weeks
T. cruris BD 2weeks
T. pedis BD 4weeks
T. manum BD 4weeks
Naftifine 1% Cream T. corporis/cruris/pedis ODBD Use 2weeks beyond
resolution of symptoms
Butenafine 1% Cream T. corporis/cruris/pedis ODBD 2-4weeks
Others
Amolorfine 0.25% Cream T. corporis BD 4weeks
Amphotericin B(1 mg) 0.1% Lipid based gel T. corporis BD 2weeks
T. corporis: Tinea corporis, T. pedis: Tinea pedis, T. manum: Tinea manum, T. cruris: Tinea cruris
interdigital tinea pedis, tinea cruris, and tinea corporis, it has a single application.[44] Successful treatment of tinea corporis
favorable safety profile.[38] Econazole nitrate foam preparation with combination of topical isoconazole with diflucotolone(a
has also shown its efficacy over foam vehicle for tinea pedis.[39] potent topical steroid) has also been reported.[45]
However, these newer drugs are costlier which in turn may lead
to issues of adherence to treatment in resourcepoor settings, Oral antifungal therapy in Tinea corporis, cruris, and
and may predispose to development of resistance. pedis
Reviewing the evidence on the use of existing oral antifungals
Finally, use of special carrier system where parent drug Systemic antifungals are indicated in case of extensive
attached to carriers such as micelle or use of nanostructured involvement and patients who fail topical therapy.[46] Out of the
lipidbased carrier, microemulsions, and vesicular systems various systemic antifungals, terbinafine, and itraconazole are
such as liposomes, niosomes, transfersomes, ethosomes, or commonly prescribed. Griseofulvin and fluconazole are also
penetration enhancer vesicles is promising as it helps in better effective but require longterm treatment. RCTs support the
bioavailability so as to attain better therapeutic response.[40] efficacy of systemic antifungals [Table3].[4750] Comparative
More recently, lipidbased amphotericin B gel has shown trial between itraconazole 100mg/day with ultramicronized
encouraging pharmacologic properties and clinical results in the griseofulvin 500mg/day for tinea corporis or tinea cruris
treatment of various mucocutaneous fungal infections including showed significantly better clinical and mycological outcome in
dermatophytosis, with no adverse effect.[41] Amphotericin B favor of itraconazole after 2weeks of therapy.[47] Similar study
incorporated in microemulsion shows a 100% increase in comparing terbinafine with griseofulvin (both 500 mg daily
skin retention with better invitro antifungal activity against for 6 weeks) for tinea corporis found mycological cure rate
T. rubrum.[42] One valid concern is whether use of topical of about 87% in former group compared to 73% in latter.[48] A
amphotericin may promote its resistance in the community, doubleblinded study between itraconazole(100mg/day) and
thereby limiting its use for more invasive fungal infections. griseofulvin(500mg/day) found itraconazole to be superior in
Microemulsion formulations of griseofulvin have shown good providing mycological cure.[49]
cure rates in dermatophytosis.[43] Adding to this is a novel
formulation of terbinafine known as terbinafine film forming Topical therapy is less effective than oral antifungals for
solution which forms a thin film forming topical application the treatment of tinea pedis, and oral treatment is generally
and fungicidal effect maintained for about 13days following given for 48 weeks. In a systematic review of efficacy of
oral antifungals in, terbinafine was found to be more effective SPECIAL SITUATIONS
than griseofulvin, whereas the efficacy of terbinafine and
itraconazole were similar.[8] In addition to antifungal therapy, Majocchis granuloma
Burrows(1% aluminum acetate or 5% aluminum subacetate) It is a deep dermatophytosis that occurs when a longstanding
wet dressings, applied for 20min 23times/day, may be superficial fungal infection causes progressive dissemination
helpful if vesiculation or maceration is present. Of various into the subcutaneous tissue. The most common etiological
types of tinea pedis, hyperkeratotic variety is more recalcitrant agent is T. rubrum.[55] Mechanical damage to the skin resulting
to treatment due to thick scales leading to ineffectiveness of from trauma may allow penetration of fungi into the reticular
topical antifungals and need for longer duration of systemic dermis, and the resulting cellular destruction and decreased
antifungals. Use of keratolytic agents and topical antifungals dermal pH makes the milieu more suitable for its survival.[56]
along with systemic antifungals has been found to be more It is mostly seen in immunocompromised hosts.[57] Topical
useful in early achievement of clinical and mycological cure steroid application leads to local immunosuppression and
as well as decreasing the duration of oral antifungals leading development of majocchi granuloma. Systemic antifungals
to better patient compliance.[51] Secondary bacterial infection such as terbinafine in a dose of 250 mg/day for 46weeks,
should be treated with oral antibiotics. Other adjunctive itraconazole 200mg twice daily for 1week/month for 2months
therapies include use of antifungal powder may help to prevent have been successfully used.[58,59] Treatment regimens with
maceration and avoidance of occlusive footwear. griseofulvin and daily itraconazole have also been suggested.[60]
topical steroids. T. mentagrophytes, instead of T. concentricum appears to be the treatment of choice for limited disease
is usually isolated from these lesions.[65] (tinea corporis/cruris/pedis). For more extensive disease, the
choice is less clear. Both terbinafine (250500 mg/day for
Antifungal therapy in immunosuppressed and 26weeks) and itraconazole (100200mg/day for 24weeks)
pregnancy appear to be effective. However, an appropriate dose and
A special subgroup of population like with HIV infection duration of administration which can produce mycologic
usually present with more extensive involvement. However, cure and prevent recurrence remains elusive. This review
characteristic morphology may be missing due to reduced also highlights the huge research gaps in the management
inflammatory component of lesion attributed to suppressed of cutaneous dermatophytosis which need to be plugged
immunity.[66] In a patient with associated comorbidities such to provide better and effective care to the patients. More
as renal, hepatic impairment, and caution should be exercised stringent RCTs are the need of the hour comparing the various
oral antifungal therapies to give a clear idea regarding the
while prescribing systemic antifungals. Terbinafine clearance
appropriate dose and duration of therapy.
significantly reduced in patient in renal impairment. So dose
should be adjusted accordingly, or drug from different group
should be preferred. Similarly, itraconazole should be avoided Financial support and sponsorship
in patient with hepatic impairment. Terbinafine is a category Nil.
B drug in pregnancy. However, there is no clear cut guideline
available for managing dermatophytic infection and treatment Conflicts of interest
should be individualized and based upon riskbenefit ratio.[67] There are no conflicts of interest.
14. Jaradat SW, Cubillos S, Krieg N, Lehmann K, Issa B, Piehler S. Low 39. ElewskiBE, VlahovicTC. Econazole nitrate foam 1% for the treatment
DEFB4 copy number and high systemic hBD-2 and IL-22 levels are of tinea pedis: Results from two doubleblind, vehiclecontrolled, phase
associated with dermatophytosis. J Invest Dermatol 2015;135:750-8. 3 clinical trials. JDrugs Dermatol 2014;13:8038.
15. GarcaRomeroMT, ArenasR. New insights into genes, immunity, and 40. BseisoEA, NasrM, SammourO, Abd El GawadNA. Recent advances
the occurrence of dermatophytosis. JInvest Dermatol 2015;135:6557. in topical formulation carriers of antifungal agents. Indian J Dermatol
16. TainwalaR, SharmaY. Pathogenesis of dermatophytoses. Indian J Venereol Leprol 2015;81:45763.
Dermatol 2011;56:25961. 41. Sheikh S, Ahmad A, Ali SM, Paithankar M, Barkate H, Raval RC, et
17. DahlMV. Dermatophytosis and the immune response. JAm Acad al.Topical delivery of lipid based amphotericin B gel in the treatment
Dermatol 1994;31(3 Pt 2):S3441. of fungal infection: A clinical efficacy, safety and tolerability study in
18. JonesHE, ReinhardtJH, RinaldiMG. Immunologic susceptibility to patients. J Clin Exp Dermatol Res 2014;5:248.
chronic dermatophytosis. Arch Dermatol 1974;110:21320. 42. ButaniD, YewaleC, MisraA. Amphotericin B topical microemulsion:
19. OliveiraCB, VasconcellosC, SakaiValenteNY, SottoMN, LuizFG, Formulation, characterization and evaluation. Colloids Surf B
Belda Jnior W, etal. Tolllike receptors(TLR) 2 and 4 expression Biointerfaces 2014;116:3518.
of keratinocytes from patients with localized and disseminated 43. AggarwalN, GoindiS, KhuranaR. Formulation, characterization and
dermatophytosis. Rev Inst Med Trop Sao Paulo 2015;57:5761. evaluation of an optimized microemulsion formulation of griseofulvin
20. KuradeSM, AmladiSA, MiskeenAK. Skin scraping and a potassium for topical application. Colloids Surf B Biointerfaces 2013;105:15866.
hydroxide mount. Indian J Dermatol Venereol Leprol 2006;72:23841. 44. LiRY, WangAP, XuJH, XiLY, FuMH, ZhuM, etal. Efficacy and
21. LasseterG, PalmerM, MorganJ, WattsJ, YoxallH, KibblerC, etal. safety of 1% terbinafine filmforming solution in Chinese patients with
Developing best practice for fungal specimen management: Audit of tinea pedis: A randomized, doubleblind, placebocontrolled, multicenter,
UK microbiology laboratories. Br J Biomed Sci 2011;68:197202. parallelgroup study. Clin Drug Investig 2014;34:22330.
22. SinghJ, ZamanM, GuptaAK. Evaluation of microdilution and disk 45. CzaikaVA. Effective treatment of tinea corporis due to Trichophyton
diffusion methods for antifungal susceptibility testing of dermatophytes. mentagrophytes with combined isoconazole nitrate and diflucortolone
Med Mycol 2007;45:595602. valerate therapy. Mycoses 2013;56Suppl1:302.
23. FernndezTorres B, Cabaes FJ, CarrilloMuoz AJ, EstebanA, 46. Lesher JL Jr. Oral therapy of common superficial fungal infections of
InzaI, AbarcaL, etal. Collaborative evaluation of optimal antifungal the skin. JAm Acad Dermatol 1999;40(6 Pt 2):S314.
susceptibility testing conditions for dermatophytes. JClin Microbiol 47. BourlondA, LachapelleJM, AussemsJ, BoydenB, CampaertH, ConincxS,
2002;40:39994003. etal. Doubleblind comparison of itraconazole with griseofulvin in the
24. GmezMoyanoE, CrespoErchigaV. Tinea of vellus hair: An indication treatment of tinea corporis and tinea cruris. Int J Dermatol 1989;28:4102.
for systemic antifungal therapy. Br J Dermatol 2010;163:6036. 48. ColeGW, StricklinG. Acomparison of a new oral antifungal, terbinafine,
25. YangCY, LinTL, TzungTY, ChengLC, WangJT, JeeSH. Direct with griseofulvin as therapy for tinea corporis. Arch Dermatol
identification of dermatophyte DNA from clinical specimens by a nested 1989;125:15379.
polymerase chain reaction assay. Arch Dermatol 2007;143:799800. 49. PanagiotidouD, KousidouT, ChaidemenosG, KarakatsanisG,
26. TheelES, HallL, MandrekarJ, WengenackNL. Dermatophyte KalogeropoulouA, TeknetzisA, etal. Acomparison of itraconazole
identification using matrixassisted laser desorption ionizationtime of and griseofulvin in the treatment of tinea corporis and tinea cruris: A
flight mass spectrometry. JClin Microbiol 2011;49:406771. doubleblind study. JInt Med Res 1992;20:392400.
27. HuiD, Xuecheng S, Aie X. Evaluation of reflectance confocal 50. F a e r g e m a n n J , M r k N J , H a g l u n d A , O d e g r d T.
microscopy in dermatophytosis. Mycoses 2013;56:1303. Amulticentre(doubleblind) comparative study to assess the safety
28. WeinsteinA, BermanB. Topical treatment of common superficial tinea and efficacy of fluconazole and griseofulvin in the treatment of tinea
infections. Am Fam Physician 2002;65:2095102. corporis and tinea cruris. Br J Dermatol 1997;136:5757.
29. GuptaAK, TomasE. New antifungal agents. Dermatol Clin 2003;21:56576. 51. ShiTW, ZhangJA, ZhangXW, YuHX, TangYB, YuJB. Combination
30. GrillotR, LebeauB. Systemic antifungal agents. In Bryskier, M.D. A (ed): treatment of oral terbinafine with topical terbinafine and 10% urea
Antimicrobial Agents. ASM Press, Washington, DC; 2005. p.126087. ointment in hyperkeratotic type tinea pedis. Mycoses 2014;57:5604.
31. HighWA, FitzpatrickJE. Topical antifungal agents. In: Fitzpatricks 52. JachietM, LanternierF, RybojadM, BagotM, IbrahimL, CasanovaJL,
Dermatology in General Medicine. 8thed. Tata McGraw Hill: New etal. Posaconazole treatment of extensive skin and nail dermatophytosis
Delhi; 2012. p.211621. due to autosomal recessive deficiency of CARD9. JAMA Dermatol
32. RottaI, ZiegelmannPK, OtukiMF, RiverosBS, BernardoNL, CorrerCJ. 2015;151:1924.
Efficacy of topical antifungals in the treatment of dermatophytosis: A 53. WongJH, LauKM, WuYO, ChengL, WongCW, YewDT, etal.
mixedtreatment comparison metaanalysis involving 14 treatments. Antifungal mode of action of macrocarpal C extracted from Eucalyptus
JAMA Dermatol 2013;149:3419. globulus Labill(Lan An) towards the dermatophyte Trichophyton
33. Havlickova B, Friedrich M. The advantages of topical combination mentagrophytes. Chin Med 2015;10:34.
therapy in the treatment of inflammatory dermatomycoses. Mycoses 54. AraiS, YoshinoT, FujimuraT, MaruyamaS, NakanoT, MukunoA,
2008;51Suppl4:1626. etal. Mycostatic effect of recombinant dermcidin against Trichophyton
34. NadaloD, MontoyaC, HunterSmithD. What is the best way to treat rubrum and reduced dermcidin expression in the sweat of tinea pedis
tinea cruris? J Fam Pract 2006;55:2568. patients. JDermatol 2015;42:706.
35. AlstonSJ, CohenBA, BraunM. Persistent and recurrent tinea corporis 55. SmithKJ, NeafieRC, Skelton HG 3 rd, BarrettTL, GrahamJH,
in children treated with combination antifungal/corticosteroid agents. LuptonGP. Majocchis granuloma. JCutan Pathol 1991;18:2835.
Pediatrics 2003;111:2013. 56. GillM, SachdevaB, GillPS, AroraB, DeepA, KaranJ. Majocchis
36. HaedersdalM, SvejgaardEL. Systematic treatment of tinea granuloma of the face in an immunocompetent patient. JDermatol
pedisEvidence for treatment? A result of a Cochrane review. Ugeskr 2007;34:7024.
Laeger 2003;165:14368. 57. Akiba H, MotokiY, Satoh M, Iwatsuki K, Kaneko F. Recalcitrant
37. Stein Gold LF, Vlahovic T, VermaA, Olayinka B, Fleischer AB Jr. trichophytic granuloma associated with NKcell deficiency in a SLE
Naftifine hydrochloride gel 2%: An effective topical treatment for patient treated with corticosteroid. Eur J Dermatol 2001;11:5862.
moccasintype tinea pedis. JDrugs Dermatol 2015;14:113844. 58. GuptaAK, PrussickR, SibbaldRG, KnowlesSR. Terbinafine in the
38. KhannaD, BhartiS. Luliconazole for the treatment of fungal infections: treatment of Majocchis granuloma. Int J Dermatol 1995;34:489.
An evidencebased review. Core Evid 2014;9:11324. 59. GuptaAK, GroenK, WoestenborghsR, De DonckerP. Itraconazole
pulse therapy is effective in the treatment of Majocchis granuloma: 65. VermaS, HayRJ. Topical steroidinduced tinea pseudoimbricata: A
A clinical and pharmacokinetic evaluation and implications striking form of tinea incognito. Int J Dermatol 2015;54:e1923.
for possible effectiveness in tinea capitis. Clin Exp Dermatol 66. MillikanLE. Role of oral antifungal agents for the treatment of
1998;23:1038. superficial fungal infections in immunocompromised patients. Cutis
60. FengWW, ChenHC, ChenHC. Majocchis granuloma in a 3yearold 2001;681Suppl: 614.
boy. Pediatr Infect Dis J 2006;25:6589. 67. ElstonCA, ElstonDM. Treatment of common skin infections and
61. RavineD, TunerKJ, AlpersMP. Genetic inheritance of susceptibility infestations during pregnancy. Dermatol Ther 2013;26:31220.
to tinea imbricata. J Med Genet 1980;17:342-8. 68. Pieiro L, LarruskainJ, IdigorasP, PrezTralleroE. Trichophyton
62. JonesHE. Immune response and host resistance of humans to rubrum syndrome: The tip of the iceberg and a preventable outcome.
dermatophyte infection. JAm Acad Dermatol 1993;28(5 Pt 1):S128. Mycoses 2010;53:186.
63. HayRJ, ReidS, TalwatE, MacnamaraK. Immune responses of patients 69. GhannoumM, IshamN, SheehanD. Voriconazole susceptibilities of
with tinea imbricata. Br J Dermatol 1983;108:5816. dermatophyte isolates obtained from a worldwide tinea capitis clinical
64. BudimuljaU, KuswadjiK, BramonoS, BasukiJ, JudanarsoLS, trial. JClin Microbiol 2006;44:257980.
UntungS, etal. Adoubleblind, randomized, stratified controlled study 70. GhannoumMA, WraithLA, CaiB, NyiradyJ, IshamN. Susceptibility
of the treatment of tinea imbricata with oral terbinafine or itraconazole. of dermatophyte isolates obtained from a large worldwide terbinafine
Br J Dermatol 1994;130Suppl43:2931. tinea capitis clinical trial. Br J Dermatol 2008;159:7113.